EDITOR: | December 29th, 2020 | 1 Comment

The marvels of graphene technology kick off 2021 with ZEN focused on our health

| December 29, 2020 | 1 Comment

While we were getting ready for Christmas, on December 22, 2020, ZEN Graphene Solutions Ltd. (TSXV: ZEN) made my head explode.

Well, almost – and there is probably a cure for that (ultimately). But in the meantime, the company’s announcement has rocked ZEN shareholder’s world with a share price increase of just over 50% in a matter of days.

In case you missed it, the press release is here (and watch a great interview with senior management here) as the company reveals the potential blockbusting impact of its graphene science. You might recall that ZEN is working on a virucidal ink for coating masks, but the most recent news is yet another example of the marvels of graphene technology.

Many people know of graphene for its strength (200 times stronger than steel) and ability to conduct heat (10 times more effective than copper) and conduct electricity (1,000 times better than copper), but the world is just coming to understand the biomedical attributes of the diamond that didn’t grow up.

Graphene is a two-dimensional, single layer “crystal” of pure carbon, which is inert. Attaching minute amounts of active “ingredients” to the graphene has resulted in a potential new compound which could be used as an antibiotic, antiviral or antifungal treatment.

That bears repeating, because this is potentially a huge breakthrough.

An alternative that could be used as an antibiotic, antiviral or antifungal treatment.

Recently received testing results from the University Health Network/Mount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a medical breakthrough in the treatment of numerous human-contracted pathogens.

The company commenced cytotoxicity (toxicity to cells) studies in lab animals in October 2020, with results expected in January 2021. Pending the outcome of the testing to demonstrate the safety of the graphene compound, upon successful completion the company will then seek to move immediately to human trials in 2021 with one or more pharma partners.

Immediate and obvious uses for a successful graphene compound product would be the potential use to treat infection of upper and lower respiratory tract – where COVID-19 is a major contributor – via a dry-powder inhaler or a nasal spray to maximize local concentrations directly at the site of infection. Other immediate obvious uses are the potential role in ear, eye, and fungal infections treatments.

If the graphene compound is shown to be safe and effective in human trials, subject to regulatory approvals, it would also provide a viable alternative to many of the antibiotic-resistant super-bugs.

Think about that – we all know someone who has had an issue with this and it is becoming unfortunately more common in hospital care.

The potential impact of this discovery and breakthrough should not be underestimated. The world has thus-far mostly focussed on the mechanical and physical aspects of using graphene as an enhancer. A new potential medical treatment? Antibiotic, antiviral or antifungal all in one?

Boom – just made my head explode….again!


Frederick Kozak is a Professional Engineer with extensive oil and gas, and international business experience and has more than 25 years involved in capital markets ... <Read more about Frederick Kozak>

Copyright © 2021 InvestorIntel Corp. All rights reserved. More & Disclaimer »


  • Mekhan

    Boom, it also made my head explode as well, I really like graphene, I was also reading about its superconducting properties, your right thousand times more conductive than copper..

    December 30, 2020 - 12:58 AM

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.